<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795206</url>
  </required_header>
  <id_info>
    <org_study_id>US-CHM-11761</org_study_id>
    <nct_id>NCT04795206</nct_id>
  </id_info>
  <brief_title>Natural Disease Progression in Participants With Choroideremia</brief_title>
  <official_title>A Retrospective Cohort Analysis of the Natural Disease Progression of Patients With Choroideremia in Real-World Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to quantify disease progression measured by best&#xD;
      corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM)&#xD;
      participants. The secondary objectives are to describe demographic and baseline clinical&#xD;
      characteristics among CHM participants and to match CHM participants in the Intelligent&#xD;
      Research in Sight (IRIS®) Registry to Biogen's investigator sponsored trial (IST) study&#xD;
      population using propensity score matching.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a retrospective cohort study of CHM eyes and participants which will include&#xD;
      all eligible participants and eyes with the first documented diagnosis of CHM from July 1st,&#xD;
      2013 to December 31st, 2019 that meet the study criteria. This study will be conducted using&#xD;
      data from American Academy of Ophthalmology's (AAO) IRIS® Registry which captures CHM&#xD;
      participant's demographics, clinical characteristics and clinical outcomes from 2013.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2020</start_date>
  <completion_date type="Actual">August 10, 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Progression of Best Corrected Visual Acuity (BCVA) in Relation to Age</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Progression of BCVA Over Time After the Baseline BCVA</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Demographics Described at Baseline</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The demographics will include age, sex, race, geographic region and treating provider specialty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matching Participants with CHM in the IRIS® Registry to Biogen's IST Study Population Using Propensity Score (PS) Matching</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>A propensity score matching approach will be performed to select eligible male CHM participants from IRIS Registry to match Biogen's IST study population. With the approach, the probability of participating in the IST study given the observed baseline participant characteristics will be estimated for each participant. Propensity score will be estimated using logistic regression and pre-specified baseline covariates including participants demographics and clinical characteristics. The propensity match will be considered adequate if all the variables between the PS-matched CHM cohort and IST study cohort have an absolute value of the standardized mean difference (SMD) in PS-score that is less than 0.1.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1178</enrollment>
  <condition>Choroideremia</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Main Cohort</arm_group_label>
    <description>All eligible participants with CHM in IRIS Registry will be included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Trial-Matched Cohort</arm_group_label>
    <description>Only male participants with CHM from Cohort 1 to match Biogen's IST study population using propensity score matching will be included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Cohort 1: Main Cohort</arm_group_label>
    <arm_group_label>Cohort 2: Trial-Matched Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Main cohort will include all eligible CHM participants in IRIS registry. Trial-matched&#xD;
        cohort will include only male CHM participants from Cohort 1 to match Biogen's IST study&#xD;
        population using propensity score matching.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Cohort 1: All CHM Participants&#xD;
&#xD;
          -  Participants with a documented diagnosis of CHM identified by the presence of&#xD;
             International Classification of Diseases (ICD)-9/10 or SNOMED coding:&#xD;
&#xD;
               1. ICD-9: 363.55&#xD;
&#xD;
               2. ICD-10: H31.2&#xD;
&#xD;
               3. SNOMED-CT: 75241009&#xD;
&#xD;
        Cohort 2: Trial-Matched CHM Participants&#xD;
&#xD;
          -  Male participants with a documented diagnosis of CHM identified by the presence of&#xD;
             ICD-9/10 or SNOMED coding:&#xD;
&#xD;
               1. ICD-9: 363.55&#xD;
&#xD;
               2. ICD-10: H31.21&#xD;
&#xD;
               3. SNOMED-CT: 75241009&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  N/A&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>X-linked inherited retinal disorder</keyword>
  <keyword>Rare disease</keyword>
  <keyword>Bilateral disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

